The impact of a novel apolipoprotein e and amyloid-β protein precursor-interacting protein on the production of amyloid-β

Journal of Alzheimer's Disease

Volumn 26, Issue 2, 2011, Pages 239-253

  Hopkins, Paul C R ^a   Sáinz Fuertes, Ricardo ^a   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; amyloid precursor protein; apolipoprotein E; TMCC2

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LIPID BINDING PROTEIN; PROTEIN TMCC2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LYSATE; ENDOPLASMIC RETICULUM; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; RAT;

EID: 80052814897     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-102115     Document Type: Article

References (58)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
2. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipopro-tein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981. (Pubitemid 23069980)
3. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25, 641-650. (Pubitemid 38686487)
4. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349, 704-706. (Pubitemid 21912142)
5. Verkkoniemi A, Somer M, Rinne JO, Myllykangas L, Crook R, Hardy J, Viitanen M, Kalimo H, Haltia M (2000) Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology. 54, 1103-1109. (Pubitemid 30151853)
6. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T; Members of the Familial Alzheimer's Disease Pathology Study Group (2001) Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 158, 2165-2175. (Pubitemid 32545202)
7. Nochlin D, Bird TD, Nemens EJ, Ball MJ, Sumi SM (1998) Amyloid angiopathy in a Volga German family with Alzheimer's disease andapresenilin-2 mutation (N141I). Ann Neurol 43, 131-135. (Pubitemid 28124661)
8. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513-517.
9. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694. (Pubitemid 30428655)
10. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phe-notype and abolished beta-amyloid generation. Nat Neurosci 4, 231-232. (Pubitemid 32194866)
11. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10, 1317-1324. (Pubitemid 32600485)
12. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
13. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17, 263-264.
14. Dodart JC, Bales KR, Johnstone EM, Little SP, Paul SM (2002) Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP (V717F) transgenic mice. Brain Res 955, 191-199 (Pubitemid 35284849)
15. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 103 2892-2897.
16. Miao J, Vitek MP, Xu F, Previti ML, Davis J, Van Nostrand WE (2005) Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci 25, 6271-6277. (Pubitemid 40962521)
17. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpressionofamyloid beta peptides but noton plaque formation. J Neurosci 22, 10539-10548. (Pubitemid 36005128)
18. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM (2005) Human apolipoprotein E4 alters the amyloid-beta 40: 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25, 2803-2810. (Pubitemid 40389238)
19. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM (2002) Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9, 305-318. (Pubitemid 34442079)
20. Xu F, Vitek MP, Colton CA, Previti ML, Gharkholonarehe N, Davis J, Van Nostrand WE (2008) Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J Neurosci 28, 5312-5320.
21. Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, Manelli A, LaDu MJ, Hyman BT, Rebeck GW (2004) Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 90, 1132-1143. (Pubitemid 39167346)
22. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, et al. (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94, 860-869.
23. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 269, 23403-23406.
24. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41, 193-202. (Pubitemid 38125181)
25. Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski JQ, Lee VM (2005) BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol 168, 291-302. (Pubitemid 40248226)
26. Ljungberg MC, Dayanandan R, Asuni A, Rupniak TH, Anderton BH, Lovestone S (2002) Neuroreport 13, 867-870.
27. Kaether C, Schmitt S, Willem M, Haass C (2006) Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 7, 408-415. (Pubitemid 43372750)
28. Wittig I, Braun HP, Schägger H (2006) Blue native PAGE. Nat Protoc (2006) 1, 418-428.
29. Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U, Klafki HW, Staufenbiel M, Hüther G, Rüther E, Kornhuber J (1997) Improved electrophoretic separation and immunoblottingofbeta-amyloid (Abeta) peptides 1-40, 1-42, and 1-43. Electrophoresis 18, 527-532. (Pubitemid 27174442)
30. Edbauer D, Winkler E, Haass C, Steiner H (2002) Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation.Proc Natl Acad Sci USA 99, 8666-8671. (Pubitemid 34693617)
31. Culvenor JG, Ilaya NT, Ryan MT, Canterford L, Hoke DE, Williamson NA, McLean CA, Masters CL, Evin G (2004) Characterization of presenilin complexes from mouse and human brain using Blue Native gel electrophoresis reveals high expression in embryonic brain and minimal change in complex mobility with pathogenic presenilin mutations. Eur J Biochem 271, 375-385. (Pubitemid 38130465)
32. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y (2006) A Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26, 4985-4994. (Pubitemid 44315280)
33. Aoki K, Uchihara T, Sanjo N, Nakamura A, Ikeda K, Tsuchiya K, Wakayama Y (2003) Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 34, 875-880. (Pubitemid 36402954)
34. Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S (1999) Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis 6, 508-514. (Pubitemid 30036620)
35. Dekroon RM, Armati PJ (2001) Synthesis and processing of apolipoprotein E in human brain cultures. Glia 33, 298-305. (Pubitemid 32285746)
36. Hirose Y, Imai Y, Nakajima K, Takemoto N, Toya S, Kohsaka S. Glial (1994) conditioned medium alters the expression of amyloid precursor protein in SH-SY5Y neuroblastoma cells. Biochem Biophys Res Commun 198, 504-509. (Pubitemid 24178397)
37. Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide J Biol Chem 280, 28110-28117. (Pubitemid 41076929)
38. Chyung AS, Greenberg BD, Cook DG, Doms RW, Lee VM (1997) Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J Cell Biol 138, 671-680. (Pubitemid 27349846)
39. Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, Haass C (1997) Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol Chem 272, 16085-16088. (Pubitemid 27276419)
40. Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA, Wirths O. (2010) Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol 119, 555-566.
41. De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, Annaert W, Van Broeckhoven C, De Strooper B (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet 10, 1665-1671. (Pubitemid 32776296)
42. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horré K, Wiltfang J, Esselmann H, De Strooper B (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms J Neurochem 96, 732-742.
43. Maltese WA, Wilson S, Tan Y, Suomensaari S, Sinha S, Barbour R, McConlogue L (2001) Retention of the Alzheimer's amyloid precursor fragment C99inthe endoplas-mic reticulum prevents formation of amyloid beta-peptide. J Biol Chem 276, 20267-20279.
44. Cupers P, Bentahir M, Craessaerts K, Orlans I, Vanderstichele H, Saftig P, De Strooper B, Annaert W (2001) The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. J Cell Biol 154, 731-740. (Pubitemid 34292955)
45. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39, 168-177. (Pubitemid 46184347)
46. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE (2005) Neu-ronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 102, 13461-13466. (Pubitemid 41420870)
47. Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ (2006) The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 26, 1596-1603. (Pubitemid 43237030)
48. Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, Bernardo A, Lin C, Wyss-Coray T, Huang Y, Mucke L (2010) Cellular Source of Apolipoprotein E4 Determines Neuronal Susceptibility to Excitotoxic Injury in Transgenic Mice. Am J Pathol 177, 563-569.
49. Suzuki T, Araki Y, Yamamoto T, Nakaya T (2006) Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J Biochem 139, 949-955. (Pubitemid 44196871)
50. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, deCalignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724. (Pubitemid 351220570)
51. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822. (Pubitemid 21917100)
52. Peters-Libeu CA, Newhouse Y, Hatters DM, Weisgraber KH (2006) Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine. J Biol Chem 281, 1073-1079.
53. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathol-ogy, including Alzheimer's disease. Proc Natl Acad Sci USA 103, 5644-5651.
54. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100, 10966-10971. (Pubitemid 37140136)
55. Zheng H, Koo EH (2006) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1, 5.
56. Nicoll JA, Roberts GW, Graham DI (1995) Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med 1, 135-137.
57. Slooter AJ, Tang MX, van Duijn CM, Stern Y, Ott A, Bell K, Breteler MM, Van Broeckhoven C, Tatemichi TK, Tycko B, Hofman A, Mayeux R (1997) Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 277, 818-821. (Pubitemid 27111318)
58. Teasdale GM, Nicoll JA, Murray G, Fiddes M (1997) Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 350, 1069-1071. (Pubitemid 27437858)